BR100 Decreased By (-0.15%)
BR30 Decreased By (-0.74%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.80 Decreased By ▼ -0.23 (-3.81%)
BML 58.03 Increased By ▲ 5.28 (10.01%)
BOP 33.85 Decreased By ▼ -0.40 (-1.17%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.77 Decreased By ▼ -0.57 (-4.62%)
FCCL 53.35 Decreased By ▼ -0.54 (-1%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.05 Decreased By ▼ -0.06 (-0.74%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.19 Decreased By ▼ -0.86 (-0.98%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.31 Increased By ▲ 0.37 (0.93%)
PIAHCLA 26.10 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.09 Decreased By ▼ -0.23 (-1.33%)
PPL 228.40 Decreased By ▼ -4.38 (-1.88%)
PRL 34.59 Decreased By ▼ -0.36 (-1.03%)
PTC 67.35 Decreased By ▼ -0.21 (-0.31%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.90 Decreased By ▼ -0.27 (-0.99%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.29 Increased By ▲ 0.53 (6.05%)
TREET 24.59 Increased By ▲ 0.05 (0.2%)
TRG 71.69 Decreased By ▼ -0.06 (-0.08%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
By

BRISBANE: Australian medical tech manufacturer Ellume said it had recalled almost 200,000 at-home Covid-19 tests in the United States over an increased chance of false positives.

Ellume's rapid at-home coronavirus test last year became the first to receive emergency use authorisation in the US.

The US Food and Drug Administration issued an alert Tuesday over the "potential for false positive results with certain lots of the Ellume COVID-19 Home Test, due to a recently identified manufacturing issue".

"Negative results do not appear to be affected by the manufacturing issue," the statement said.

"The FDA is working closely with Ellume to assess the company's additional manufacturing checks and other corrective steps to help ensure that the issue is resolved."

A spokesman for Ellume told AFP on Wednesday that 195,000 of the 3.5 million tests shipped to the United States had been affected.

Among them were tests provided to the Department of Defense for distribution to community health programmes.

In a statement dated October 1, the company said the voluntary recall was ordered after false positive results were reported in some product batches at higher rates than expected.

"I offer my sincere apologies -- and the apologies of our entire company -- for the stress or difficulties people may have experienced due to a false positive result," founder Sean Parsons said.

The firm said it had identified the cause of the issue and implemented additional controls, and had resumed distributing the tests to US retailers.

"We have and will continue to work diligently to ensure test accuracy, in all cases," Parsons added.

Comments

Comments are closed for this article.